Comment on “Exosomal CCT3 as a biomarker for diagnosis and immune therapy response in patients diagnosed with hepatocellular carcinoma.”

作者：Fei Cheng, Cun Wang · 发表于：Digestive and Liver Disease · 年份：2025 · DOI：10.1016/j.dld.2025.08.063 · 研究领域：Extracellular vesicles in disease、Galectins and Cancer Biology、Circular RNAs in diseases

We read with great interest the recently published SCI article in your journal entitled “Exosomal CCT3 as a biomarker for diagnosis and immune therapy response in patients diagnosed with hepatocellular carcinoma” [1]. Early diagnosis of hepatocellular carcinoma (HCC) and accurate evaluation of immunotherapy efficacy represent both cutting-edge research areas and pressing clinical challenges in the field. Effectively addressing these issues holds great promise for improving outcomes and benefiting a large population of patients with HCC.